{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-26-000036","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.136836+00:00","generated_at":"2026-05-14T23:17:06.216696+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xencor reports final Phase 1 data for XmAb942; predicts superior TL1A inhibition vs first-gen antibodies","bullets":["XmAb942 achieved 74.1-day half-life; supports single SC dose every 12 weeks during maintenance.","Modeling predicts >99% TL1A inhibition in 86% of patients during induction vs 31-40% for first-gen.","No serious TEAEs; ADA incidence 57% across doses but 0% neutralizing at high-dose tested in Phase 2b.","Global Phase 2b XENITH-UC enrollment on track; primary endpoint results expected H2 2027.","First-in-human study for XmAb412 (TL1A x IL23p19) on track to start in Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-26-000036","json":"https://secwatch.observer/filing/0001326732-26-000036.json","markdown":"https://secwatch.observer/filing/0001326732-26-000036.md","text":"https://secwatch.observer/filing/0001326732-26-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673226000036/0001326732-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673226000036/xncr-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:17:06.216696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}